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BACKGROUND: The alirocumab expanded use program provided open-label access to alirocumab
before its commercial availability to patients with severe hypercholesterolemia not controlled with
maximally tolerated doses of standard-of-care lipid-lowering therapy.
OBJECTIVE: To describe the safety and lipid-lowering efficacy of alirocumab in high-risk patients
whowere likely to be early users of proprotein convertase subtilisin/kexin type 9 inhibitors after approval.
METHODS: Patients with heterozygous familial hypercholesterolemia (HeFH) and/or coronary heart
disease (CHD) and baseline low-density lipoprotein cholesterol (LDL-C) of$160 mg/dL on maximally
tolerated lipid-lowering therapy were enrolled and received alirocumab 150 mg every 2 weeks for
24 weeks. Patients were permitted use of all available statins; those not taking any dose of statin could
also be enrolled.
RESULTS: Of 100 enrolled patients, 93 were white, 62 were women, and overall mean age was
58 years; 61 had HeFH, 3 had unknown type of familial hypercholesterolemia, 66 had CHD, and 30
had both familial hypercholesterolemia and CHD. Sixty-four patients were identified by their providers
to have some level of statin intolerance; of these, 47 were not on statin. Alirocumab reduced LDL-C on
average from 221 mg/dL at baseline to 102 mg/dL by week 24 (255%). Treatment-emergent adverse
events were experienced in 61% of patients and treatment-emergent adverse events leading to permanent
treatment discontinuation in 3% of patients; no deaths occurred.
CONCLUSIONS: Safety and efficacy observations from the open-label alirocumab expanded use
program of very high-risk patients with HeFH and/or CHD and baseline LDL-C of $160 mg/dL
uncontrolled by maximally tolerated lipid-lowering therapy were consistent with those in the
placebo/ezetimibe-controlled ODYSSEY trials.
 2018 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Patients with severely elevated low-density lipoprotein
cholesterol (LDL-C) levels have increased risk of
cardiovascular disease and may require additional
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LDL-C-lowering treatment in addition to statin and other
nonstatin therapies.1–3 The proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitor alirocumab has been shown
in the ODYSSEY phase 3 clinical trial program to be gener-
ally well tolerated and produce significant reductions in
LDL-C and other lipid levels in patients with heterozygous
familial hypercholesterolemia (HeFH),4–7 statin intoler-
ance,8 and high cardiovascular risk.7,9,10 The results of
the ODYSSEY phase 3 trials supported the approval of alir-
ocumab in July 2015 as adjunct therapy to diet and maxi-
mally tolerated statin therapy in patients with HeFH or
clinical atherosclerotic cardiovascular disease who need
additional LDL-C reduction.11
Before its approval in the US, based on numerous
requests for access to alirocumab by health care providers,
Sanofi and Regeneron Pharmaceuticals, Inc., implemented
an expanded use program for alirocumab in high-risk
patients who met stringent eligibility criteria. Based on
clinical data from the ODYSSEY phase 3 trials, and in
accordance with the US Food and Drug Administration
regulations,12 this program was restricted to patients with
HeFH or coronary heart disease (CHD) with severe hyper-
cholesterolemia not controlled with maximally tolerated
standard-of-care lipid-lowering therapy.
Safety and lipid-lowering efficacy of alirocumab
(150 mg every 2 weeks [Q2W] for 24 weeks) were assessed
in very high-risk patients with severe hypercholesterolemia
who were likely to be early users of PCSK9 inhibitors after
approval. Observations from this program provide insight
into early clinical use of alirocumab in high-risk patients
that are complementary to the clinical findings from the
ODYSSEY program.
Methods
The alirocumab expanded use program was a prospec-
tive, multicenter, single arm, open-label, expanded-access
program in the US. The program included patients with
HeFH and/or CHD and baseline LDL-C of $160 mg/dL
($4.14 mmol/L) on standard-of-care maximally tolerated
lipid-lowering therapy in addition to diet for at least
3 months. Unlike most of the ODYSSEY development
studies, which required all patients to be taking maximally
tolerated doses of simvastatin, atorvastatin, or rosuvastatin,
the expanded use program permitted use of all available
statins (which were to be at maximal tolerated doses); high-
dose statin was defined as the highest dose of each statin.
Patients who were documented as being unable to tolerate
any dose of statin were included in the program. Diagnosis
of HeFH was required to be made either by genotyping or
by clinical criteria based on either the Simon Broome
criteria (with a diagnosis of ‘‘definite familial hypercho-
lesterolemia [FH]’’)13,14 or the World Health Organization/
Dutch Lipid Network criteria (score . 8 points).14 CHD
was defined as one or more of the following: acute myocar-
dial infarction, silent myocardial infarction, unstable
angina, coronary revascularization procedure (eg, percuta-
neous coronary intervention or coronary artery bypass graft
Figure 1 Patient flow through the alirocumab expanded use program. AE, adverse event; Q2W, every 2 weeks.
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surgery), or clinically significant CHD diagnosed by inva-
sive or noninvasive testing (such as coronary angiography,
stress test using treadmill, stress echocardiography, or nu-
clear imaging).
Enrollment into the program ended once alirocumab was
approved in the US. All participants provided written
informed consent. The program protocol was approved by
the appropriate institutional review boards, and the program
was conducted in accordance with the Declaration of
Helsinki and applicable amendments and International
Conference on Harmonization guidelines for Good Clinical
Practice.
Following a screening period of up to 4 weeks to
determine patient eligibility, enrolled patients received
alirocumab 150 mg Q2W by subcutaneous injection for a
treatment duration of 24 weeks. As an open-label expanded
use program, the primary objective was to provide access to
alirocumab before its commercial availability in high-risk
patients in need of additional LDL-C lowering despite
maximally tolerated lipid-lowering therapy. The secondary
objectives included the documentation of alirocumab safety
and efficacy over the 24-week treatment duration. Safety
endpoints included rates of adverse events (AEs), assessed
throughout the duration of the program in the safety
population (defined as patients who received at least part
of one dose of alirocumab). Investigators were asked to
characterize each AE as related or not related to alirocu-
mab. The primary efficacy endpoint of interest was the
percentage change of LDL-C from baseline at week 24;
percentage changes in other lipids from baseline at week 24
were also assessed. The efficacy population included
patients who received at least part of one dose of
alirocumab and had an available on-treatment LDL-C value
at week 24. This definition of the efficacy population is
consistent with that of the modified intention-to-treat
population that was used in the ODYSSEY trials, but
with one key difference: the modified intention-to-treat
population in the ODYSSEY trials allowed missing values
at week 24 to be accounted for by using the mixed-effect
model repeat measurement statistical approach, whereas
the protocol for the alirocumab expanded use program
(since it was an open-label single arm study, not a
randomized controlled trial) specified that all analyses
were descriptive and presented based on observed data
Table 1 Baseline characteristics and lipid levels by FH status and in the overall population
Study parameters, n (%), unless otherwise specified FH (n 5 64) Non-FH (n 5 36) Overall (n 5 100)
Age (y), mean (SD) 55.1 (12.1) 63.8 (10.6) 58.2 (12.2)
,55 32 (50.0) 7 (19.4) 39 (39.0)
55–,65 14 (21.9) 12 (33.3) 26 (26.0)
$65 18 (28.1) 17 (47.2) 35 (35.0)
Male 23 (35.9) 15 (41.7) 38 (38.0)
White 59 (92.2) 34 (94.4) 93 (93.0)
FH 64 (100.0) 0 64 (64.0)
HeFH 61 (95.3) 0 61 (61.0)
Unknown 3 (4.7) 0 3 (3.0)
CHD 30 (46.9) 36 (100.0) 66 (66.0)
Hypertension 37 (57.8) 29 (80.6) 66 (66.0)
Diabetes 8 (12.5) 2 (5.6) 10 (10.0)
Current smoker 7 (10.9) 5 (13.9) 12 (12.0)
High-dose statin* 26 (41.3) 9 (25.0) 35 (35.0)
Statin intolerant 37 (57.8) 27 (75.0) 64 (64.0)
No statin 26 (41.3) 21 (58.3) 47 (47.0)
Reduced statin dose* 11 (17.5) 6 (16.7) 17 (17.0)
Any nonstatin LLT 24 (37.5) 11 (30.6) 35 (35.0)
Ezetimibe 20 (31.3) 8 (22.2) 28 (28.0)
Baseline lipid levels, mean (95% CI), unless otherwise specified, mg/dL
LDL-C 227.9 (213.0–242.8) 207.9 (196.5–219.3) 220.7 (210.2–231.2)
Non-HDL-C 264.2 (248.4–279.9) 244.1 (231.9–256.3) 256.9 (245.8–268.0)
Total cholesterol 315.9 (300.1–331.8) 293.7 (281.0–306.4) 307.9 (296.6–319.2)
Triglycerides 173.1 (152.7–193.6) 180.5 (152.7–208.3) 175.8 (159.4–192.2)
Median (Q1:Q3) 147.5 (107.0:217.5) 164.0 (124.5:210.0) 156.5 (110.0:215.0)
HDL-C 51.8 (48.7–54.8) 49.6 (46.2–53.0) 51.0 (48.7–53.3)
CHD, coronary heart disease; CI, confidence interval; FH, familial hypercholesterolemia; HeFH, heterozygous familial hypercholesterolemia; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; non-HDL-C, non–high-density lipoprotein
cholesterol; Q1:Q3, interquartile range; SD, standard deviation.
*High-dose statin was defined as the highest dose of each available statin, and reduced statin dose included all other statin doses. One patient
declined to take statin. At baseline, using statin intensity categories as defined per the ACC/AHA guideline,15 29 patients (29.0%) were on high-
intensity statin and 23 patients (23.0%) were on moderate-/low-intensity statin.
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only (in other words, statistical approaches such as mixed-
effect model repeat measurement to account for missing
data at week 24 were not used). Descriptive statistics used
to analyze endpoints included number, mean, median,
interquartile range (Q1 and Q3), maximum, and standard
deviation and 95% confidence intervals.
Results
Baseline characteristics
Twenty-five clinical sites in the US screened 164
patients and enrolled 100 patients (Fig. 1). Of the 100
enrolled patients, 86 completed alirocumab treatment for
up to 24 weeks, 83 of whom had available data at week
24. Of the 14 patients who did not complete the program
(Fig. 1), 13 were statin intolerant, and 1 was not statin intol-
erant. Three of the 14 patients discontinued due to AEs (see
Safety), and 6 patients did not wish to continue (1 of whom
discontinued because US approval provided access to com-
mercial alirocumab without repeated clinic visits and blood
draws) (Fig. 1). Two patients discontinued due to lack of
treatment efficacy (per investigators’ judgment; 1 was
likely due to lack of compliance, and the other was due
to an unknown reason), and 3 patients did not complete
the program for other unspecified reasons (Fig. 1).
The baseline characteristics of the 100 enrolled pa-
tients are shown in Table 1. The majority of patients were
white (93%) and female (62%), with a mean age of
58 years. Sixty-four patients had FH (61 patients had
confirmed HeFH, and 3 had unknown type of FH), 66
had CHD, and 30 had both FH and CHD; baseline charac-
teristics by FH status are also shown in Table 1. Sixty-six
patients had hypertension, 10 had diabetes, and 12 were
smokers.
Of the 100 enrolled patients in the expanded use
program, 35 were on high-dose statin at baseline. One
patient declined to take statin. Sixty-four patients were
statin intolerant as reported by the investigators; 47 of these
64 patients were not on a statin and 17 were on reduced
statin dose at baseline. Thirty-five were on nonstatin lipid-
lowering therapy; of these, 28 were receiving ezetimibe
(Table 1).
Safety
Rates of treatment-emergent AEs are shown in Table 2.
Serious AEs were experienced by 6 (6%) patients
(Table 2).
As mentioned previously, 3 patients discontinued due to
AEs (Table 2 and Fig. 1). Two patients discontinued due to
myalgia (1 in the lower extremities ascribed to pravastatin,
and the other due to unknown etiology [this patient was not
on statin]). One patient discontinued due to low neutrophil
count, indicated by low white blood cell count, of unknown
cause and of moderate intensity (this patient was on statin);
the patient did not receive any corrective treatment and
recovered from the event without sequelae.
No deaths occurred, and there was one case of an AE of
special interest (cognitive disorder), which was nonserious
in nature consisting of recent memory disorders and
Table 2 Safety analysis
Patients with at least 1 TEAE
Overall (N 5 100)
All, n (%) Potentially related*, n (%)
Any TEAE 61 (61.0) 26 (26.0)
Any treatment-emergent SAE 6 (6.0) 0
Cellulitis 1 (1.0) 0
Non–Hodgkin’s lymphoma 1 (1.0) 0
Pancreatitis 1 (1.0) 0
Peptic ulcer 1 (1.0) 0
Upper gastrointestinal hemorrhage 1 (1.0) 0
Non–cardiac chest pain 1 (1.0) 0
Any TEAE leading to permanent treatment discontinuation 3 (3.0) 2 (2.0)
Myalgia 2 (2.0) 1 (1.0)
Neutrophil count decreased 1 (1.0) 1 (1.0)
Any TEAE leading to death 0 0
Any AEs of special interest† 1 (1.0) 0
Cognitive disorder 1 (1.0) 0
AE, adverse event; TEAE, treatment-emergent adverse event; SAE, serious adverse event.
*AEs considered by the investigator to be potentially related to study medication.
†AEs of special interest included increase in alanine aminotransferase (ALT) $3 ! upper limit of normal (ULN; if baseline ALT , ULN) or ALT $2
times the baseline value (if baseline ALT $ ULN); allergic events (including local injection-site reactions that are allergic in nature) requiring consul-
tation with another physician; pregnancy occurring in a female participant or the partner of a male participant; symptomatic overdose (accidental or
intentional) with alirocumab; neurologic events requiring additional examinations/procedures and/or consultation with a specialist; and neurocognitive
events.
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thinking disorders of moderate intensity that did not require
treatment discontinuation or corrective treatment; this
patient had a known medical history of similar cognitive
impairment symptoms on statin therapy and was therefore
recommended by the investigator to be observed without
neurologist consultation (the patient recovered from the
event without sequelae).
Efficacy
Alirocumab 150 mg Q2W reduced LDL-C on average
from 221 mg/dL at baseline to 102 mg/dL (255%) at week
24 (Fig. 2). Ninety-seven participants completed 12 weeks
of treatment; of these, 35 (36.1%) and 56 (57.7%) patients
achieved LDL-C of ,70 mg/dL and ,100 mg/dL at week
12, respectively. Eighty-three subjects completed 24 weeks
of treatment; of these, at week 24, 25 (30.1%) and 53
(63.9%) patients achieved LDL-C of ,70 mg/dL and
,100 mg/dL, respectively, and 54 (65.1%) patients had
LDL-C reductions $50% at week 24.
In the overall population, alirocumab reduced non–
high-density lipoprotein cholesterol (250%), total
cholesterol (240%), and triglycerides (211%) and
increased high-density lipoprotein cholesterol (110%),
from baseline to week 24 (Fig. 2). The percent reduc-
tions in LDL-C and other lipid levels on alirocumab at
week 24 by FH status and by statin comedication status
are shown in Figure 2A, B, respectively. Of the 64 statin-
intolerant patients enrolled in this program, 51 completed
the study; 12 (23.5%) and 31 (60.8%) of whom had
LDL-C levels of ,70 mg/dL and ,100 mg/dL at week
24, respectively.
Discussion and conclusions
In the alirocumab expanded use program, treatment
with alirocumab 150 mg Q2W reduced LDL-C levels in
patients with HeFH and/or CHD with baseline LDL-C of
$160 mg/dL on average from 221 mg/dL at baseline to
Figure 2 Percent changes from baseline at week 24 in LDL-C and other lipid levels on alirocumab by (A) familial hypercholesterolemia
(FH) status and (B) statin comedication status. N values represent the number of patients at week 24. The overall population pool included
the patient who declined to take statin; this patient was not included in the ‘‘no statins’’ subgroup. CI, confidence interval; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein cholesterol.
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102 mg/dL by week 24 (255%) and allowed the majority
of patients to achieve guideline-recommended LDL-C
reductions of $50%.3 The percent reductions in LDL-C
on alirocumab were similar in patients with and without
FH, and regardless of statin dose. The safety and efficacy
observations with alirocumab in this open-label program,
which included very high-risk and difficult to treat patients
with uncontrolled LDL-C who had exhausted other lipid-
lowering treatment options, were consistent with those in
the ODYSSEY trials4,5,7,8,16,17 as well as pooled subanaly-
ses of patients with HeFH6 and by statin type and dose.18
Although this expanded use program required patients to
be on maximally tolerated statin therapy as in the majority
of ODYSSEY trials, this program was distinct from most
ODYSSEY trials (which permitted only simvastatin, ator-
vastatin, or rosuvastatin) as patients were permitted to use
all available statins. Moreover, patients who were docu-
mented as being unable to tolerate any dose of statin were
included in the program. This distinction in the enrollment
criteria, which reflects real-world clinical practice, makes
the observations from the expanded use program more
relevant for real-world application. The high proportion
(64%) of statin-intolerant patients enrolled in this program
(who consisted 13 of the 14 patients [93%] that did not
complete the 24-week treatment period) highlights statin
intolerance as an important real-world clinical-therapeutic
challenge, particularly among those with very high levels of
LDL-C, though it should be noted that statin intolerance in
this program was based on provider and patient judgment
and was not systematically assessed. The observations from
this program were consistent with analyses of real-world
use of PCSK9 inhibitors, which also indicate high rates of
statin intolerance and higher LDL-C levels among users of
PCSK9 inhibitors.19–22
Although the alirocumab expanded use program started
before the approval of alirocumab in the US, the inclusion
criteria are similar to the approved indications for alirocu-
mab. Moreover, the characteristics of patients enrolled in
this program align with patient characteristics that are
highlighted in recent US guidelines/recommendations.3,23
Likewise, a retrospective analysis of real-world PCSK9 in-
hibitor prescribing data from electronic medical records in
Accenture’s ‘‘Predictive Health Intelligence Environment’’
database showed that alirocumab was mainly prescribed
to those with clinical atherosclerotic cardiovascular disease,
HeFH, and high baseline LDL-C levels. Furthermore,
compared to those without prescriptions for PCSK9 inhib-
itors, fewer patients with prescriptions for PCSK9 inhibi-
tors were on high-intensity statins, but more were taking
ezetimibe, other nonstatin lipid-lowering therapies, or no
lipid-lowering therapies.22
Observations from this expanded use program provide
insight into the characteristics of high-risk patients who
were selected by their health care providers to be early
users of PCSK9 inhibitors. In these high-risk patients, a
high proportion of whom had some degree of statin
intolerance, overall LDL-C levels were reduced by 55%
and the majority of patients achieved the guideline-
recommended LDL-C reductions of $50%.3
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